|
|
CN
Online Message×
Click switch

ContainprotacContent

Sep 15,2021
The 19th Annual San Diego BioPharma Conference
Agenda 9:00 am Welcome and Opening Remarks Tao Wu, PhD, President, SABPA Yi Liu, PhD, Chair, BioPharmaCommittee, SABPA; CEO, Kumqat Biosciences 9:15 am Floyd Romesberg,
More
Jul 21,2021
PROTAC and LYTAC
Most drugs block or modulate the function of the target protein by binding to a specific site of the target protein. However, the activity of many proteins cannot be changed in this way. Protein degradation agents represented by Proteolis-Targeting Chimaeras (PROTACs) can change the function of proteins in an unconventional way. This new type ofRead more
More
Jun 03,2021
Medicilon PROTAC Drug Discovery Research Platform
PROTAC technology has a unique mechanism The PROTAC molecule specifically recognizes and binds to the target protein through the target protein ligand (POI Ligand) at one end and the E3 Ligase through the E3 Ubiquitin Ligase Ligand (E3 Ligase Ligand) at the other end.Forming the POI-PROTAC-E3 Ligase Ternary ComplexIn this ternary complex, the target proteinRead more
More
Apr 28,2021
LYTAC technology, a lysosomal degradation technology
Targeted protein degradation is an emerging direction in the field of drug development. 40% of human genes encode extracellular proteins or membrane proteins. The degradation of cell membrane proteins is usually accomplished through lysosomal pathways. lysosome targeting chimeras lytacs (Lytac technology) are an innovative technology that degrades cell membrane or extracellular proteins, enabling degradation ofRead more
More
Dec 04,2020
CGeneTech and Medicilon Held the Conference Titled “PROTAC Project Contract Signing & Kick-off Meeting”
Shanghai, China, Dec. 2nd, 2020 — CGeneTech (Suzhou, China) Co., Ltd and Medicilon Inc. successfully held the conference titled “PROTAC project contract signing & kick-off
More
Oct 09,2020
PROTAC is first showing its edge, SD-36 has excellent anti-tumor effect
On November 11, the team of Chinese-American Wang Shaomeng published a paper titled “A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo” in the scientific journal Cancer Cell, which immediately stirred up thousands of people. Layers of waves have brought PROTAC technology back to people’s sight. Shanghai Medicilon Biopharmaceutical Co.,Read more
More
Oct 09,2020
LYTAC was born, fighting side-by-side with PROTAC to target non-medicable targets
The advent of PROTAC The advent of PROTAC has brought solutions to targets that traditional small-molecule drugs cannot be made into. After 2017, PROTAC technology has developed rapidly, from the laboratory to the industrial world, starting from Harvard University, Yale University, Arvinas, C4, Kymera Therapeutics have been established to specialize in PROTAC technical drug research,Read more
More
Jun 23,2020
Spotlight on PROTAC: Make “Undruggable” Targets Drugable
As researchers continue to explore new drug research and development, in recent years, there have emerged like protein motion (Protein Motion), targeted protein degradation complexes (PROTACs), gene transcription simulation (Transcriptional mimetic), small molecule co-receptor targeting ( SMART) and other emerging drug research and development technologies. As far as the overall development of drug research andRead more
More